Stay Informed: Transforming Radiology with Structured Reporting and Data-Driven Approaches

Dive into our activities, projects, and product updates. Catch on the latest industry news and learn who we are as a company and as a team.

Assessment time halved: Importance of a good tumor response assessment tool in clinical site reads

The Clinical Research Imaging Core (CRIC) of the University of Wisconsin Carbone Cancer Center (UWCCC) recently published a poster at the AACI CRI conference titled “Shared Investment to Build a Strong, Streamlined, and Accessible RECIST Foundation in Clinical Research”. On this poster, core manager Mr. Alex Arbuckle and faculty lead Dr. Steve Cho discuss that the previous tumor response assessment service they were using was “inflexible, cumbersome, did not align with research aspirations, and was cost prohibitive.”.

Through a joint review of various solutions, they arrived at the decision to implement mint Lesion as their centralized tumor response assessment system. The joint investment and implementation of mint Lesion by the UWCCC and UW Department of Radiology Medical Imaging Research Support has greatly improved the inclusion of imaging expertise in the assessments. Since then, it has “improved cost effectiveness, continually improved assessment time to completion, and has allowed for quick start-up and navigation of investigator initiated trials.” In the first 9 months, they were able to expand from 5 users in 2 programs to 12 users in 6 programs and halved the time required for completing an assessment.

Read the full poster by clicking here: Link to AACI CRI poster

Related Resources

Related Resources

RECIST measurements of a patient with uveal melanoma and hepatic metastases

University Hospital Tuebingen: Study compares the Efficacy of SIRT and CS-PHP in Uveal Melanoma with Hepatic Metastasis

A study[1] conducted by researchers at University Hospital Tuebingen retrospectively compared the efficacy of two liver-targeted therapies,…

Study Analyzing the Tumor Growth Rate as a Prognostic Biomarker in Lymphoma Patients Under CAR T-Cell Therapy

University Hospital Munich (LMU): Study Analyzing the Tumor Growth Rate as a Prognostic Biomarker in Lymphoma Patients Under CAR T-Cell Therapy

A recent study[1] conducted by researchers at the University Hospital Munich (LMU) investigated the role of tumor growth rate (TGR) in predicting the…

A picture of a person looking at a brain scan and the interface of mint Lesion™  on a computer

Advancing Neuro-Oncology Assessments: Mint Medical to Integrate Newly Published RANO 2.0 Criteria into mint Lesion™

Glioblastomas and other gliomas are the most common malignant primary brain tumor types, yet few effective therapies are available. Clinical research…